Private limited company · Oslo
KLYV THERAPEUTICS AS
ActiveResearch and experimental development on natural sciences and engineering (72.100)
The life line 2023–2026
Operating revenue per year, with recorded events above. As a table
Operating revenue 2025: NOK 2.2m.
Sources: the Register of Company Accounts (company accounts), fetched 4 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.
In brief
KLYV THERAPEUTICS AS is a private limited company in Oslo, founded in 2023, in the industry research and experimental development on natural sciences and engineering. The chief executive is Maria Vistnes, and the chair of the board is Renée Christine Amundsen. In 2025 the company had NOK 2.2m in operating revenue and a net profit of NOK −1.1m. The largest owner is SPRINGHEART HOLDING AS with 77.5%.
Put together by Intelligo from the sections below; each figure stands with its source where it belongs.
Overview
§ 01 Latest changes
4 changes, latest 8 Oct 2026
- Changed capital 121816 → 140328
- New articles of association 1 Jul 2026
- Endring av kapital
- Endring av vedtektsdato
Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →
Overview
§ 02 Worth knowing
2 points
- Note3 of 5 on the board are new in the last 12 months
- OKEquity ratio 85.2%, above the industry median
Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate
Overview
§ 03 Key figures
Revenue NOK 2.2m in 2025
Revenue
NOK 2.2m
+136.1% from 2024
20232025
Operating profit
NOK −1.1m
−759.9% from 2024
20232025
Net profit
NOK −1.1m
−962.2% from 2024
20232025
Equity
NOK 6.7m
+828.5% from 2024
20232025
Source: the Register of Company Accounts, read 4 Nov 2026 · The full accounts →
Finances
§ 04 Where the money comes from and goes
Financial year 2025
Of every krone of operating revenue in 2025:
- Operating costs 148%
Costs exceeded revenue: the operating result was NOK −1.1m.
Source: the Register of Company Accounts, read 4 Nov 2026
Finances
§ 05 Financial health
Equity ratio 85.2%
- KLYV THERAPEUTICS AS, 2025
- Industry median, assumed: NOK 1.5m · −4.4% · 48.9% · +3.0%
Equity NOK 6.7m85% of the assets (NOK 7.8m)
Source: the Register of Company Accounts, read 4 Nov 2026. The median is derived by Intelligo from 694 companies in 72.100 Research and experimental development on natural sciences and engineering, not stated by the source.
Finances
§ 06 Accounts
3 years, latest 2025
| NOK 1,000 | 2023–25 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating revenue | 2,207 | 935 | 0 | |
| Operating profit | −1,065 | 161 | −0 | |
| Profit before tax | −1,061 | 158 | −0 | |
| Net profit | −1,061 | 123 | −0 | |
| Total assets | 7,816 | 934 | 94 | |
| Equity | 6,662 | 718 | 94 | |
| Liabilities | 1,154 | 217 | 0 |
Source: the Register of Company Accounts, read 4 Nov 2026 · All 3 years →
Management and ownership
§ 07 Officers
7 officers now
- Maria VistnesChief executive since 2023
- ENORA ASAccountant
- Renée Christine AmundsenChair of the board since 2026
- Maria VistnesBoard member since 2023
- Beret Luise SundetBoard member since 2024
- Andreas BergBoard member since 2026
Source: the Brønnøysund Register Centre, read 23 Aug 2026 · All 7 roles, former ones too →
Management and ownership
§ 08 Signature, procuration and authorisations
3 valid powers of attorney
The board has 3 authorisations in force now: capital increase, until 18 May 2027; fullmakt konvertibelt lån, until 18 May 2027; acquisition of own shares, until 2 Dec 2026.
Source: authorisations from the announcements of the Register of Business Enterprises, read 1 Nov 2026
Management and ownership
§ 09 Owners
4 shareholders · largest 77.5%
| Owner | Share |
|---|---|
| SPRINGHEART HOLDING AS | 77.5% |
| TAILORMADE INVEST AS | 19.8% |
| PRECO AS | 1.4% |
| 1 others | 1.2% |
Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 30 Jul 2026 · All 4 owners →
Management and ownership
§ 10 Group
None registered
Not a group.No subsidiaries in the shareholder register, and no group accounts. Checked 15 Nov 2026.
Management and ownership
§ 11 Portfolio
None registered
No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.
Management and ownership
§ 12 Network
21 connections
- Person
- Company
5 people link KLYV THERAPEUTICS AS to 16 other companies: Renée Christine Amundsen 5, Andreas Berg 3, Jan Fikkan 4, Maria Vistnes 2 and Beret Luise Sundet 2.
Source: the Brønnøysund Register Centre, read 23 Aug 2026 · Explore the network →
Events and registers
§ 13 Events
29 since 2023
Events per year
20232026
Since 2023: 25 announcements and 4 register changes. Most happened in 2025 and 2026.
Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 1 Nov 2026. Register changes are Intelligo's own observations. · All 29 events →
Events and registers
§ 14 Notices
25, latest 7 Oct 2026
- Kapital
- Vedtektsdato
- Erverv av egne aksjer-fullmakt
Source: The Brønnøysund Register Centre's announcements ↗, read 1 Nov 2026 · All 25 →
Events and registers
§ 15 Charges
Not fetched yet
Events and registers
§ 16 Other registers
Found in 3 of 7
- The Central Coordinating RegisterRegistered 24 Oct 2023
- VATRegistered
- The Register of Business EnterprisesRegistered 24 Oct 2023
- The Cleaning RegisterNot registered
- The Register of Staffing AgenciesNot registered
- Smiley scheme, the Norwegian Food Safety AuthorityNot registered
- The Financial Supervisory Authority's licence registerNot registered
Purpose: Utvikle og investere i legemidler, legemiddelkandidater, hjelpemidler, verktøy og metoder for pasientbehandling og persontilpasset medisin.
Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026
Market
§ 17 Tenders
None registered
No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.
Market
§ 18 Vacancies
None registered
No vacancies.No open ads at NAV. Checked 15 Nov 2026.
Market
§ 19 Competitors
Industry code 72.100
The companies most like it:
Compare themThe selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →
Last
§ 20 Questions and answers
5 questions
- Who is the chief executive of KLYV THERAPEUTICS AS?
Maria Vistnes, since 2023. § 07 - Who owns KLYV THERAPEUTICS AS?
4 shareholders. The largest is SPRINGHEART HOLDING AS with 77.5%, TAILORMADE INVEST AS with 19.8% and PRECO AS with 1.4%. § 09 - What was the revenue in 2025?
NOK 2.2m in the company. § 06 - Where is KLYV THERAPEUTICS AS based?
Gaustadalléen 21, 0349 Oslo. - When was KLYV THERAPEUTICS AS founded?
30 Aug 2023, registered in the Register of Business Enterprises 24 Oct 2023. § 16
The answers come from the sections linked to, with their sources.